SLC5A2 and heart failure: However, whether therapy with SGLT2 inhibitors, in addition to therapy with ARNI, in patients with heart failure with reduced ejection fraction is effective in terms of reverse myocardial remodeling and reducing the risk of adverse cardiovascular events remains subject to study.